# US 2001/0026937 A1 · Monocyte-derived dendritic cell subsets

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0026937 A1
- Document ID: US20010026937A1
- Status: Published application
- Kind: A1
- Application number: 09/760,388
- Filed: 2001-01-10
- Published: 2001-10-04
- Earliest claimed: 2000-01-11
- Inventors: Juha Punnonen; Chia-Chun J. Chang
- Web page: https://patentgrep.com/patent/US20010026937A1

## CPC

- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/40: characterised by antigens that are targeted or presented by cells of the immune system
- C12N 5/064: {Immunosuppressive dendritic cells}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2500/36: Lipids
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2501/23: Interleukins [IL]
- C12N 2501/24: Interferons [IFN]
- C12N 2501/52: CD40, CD40-ligand (CD154)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A novel subset of monocyte-derived dendritic cells are provided. Methods for producing these monocyte-derived dendritic cells and compositions comprising the dendritic cells of the invention are also provided. Methods for inducing an immune response to an antigen of interest using the dendritic cells of the invention are provided. Also provided are methods for therapeutically or prophylactically treating a disease in a subject suffering from the disease using the dendritic cells.

## Claims

### Claim 1

A method of producing a differentiated antigen presenting cell (APC), the method comprising: culturing a population of peripheral blood or bone marrow mononuclear cells in interleukin-4 (IL-4), granulocyte macrophage colony stimulating factor (GM-CSF), and a culture medium comprising insulin, transferrin, linoleic acid, oleic acid, palmitic acid for a sufficient time to produce the differentiated antigen presenting cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the differentiated APC is a dendritic cell.

### Claim 3 (depends on 2)

The method of claim 2, wherein the dendritic cell produces substantially no IL-12.

### Claim 4 (depends on 3)

The method of claim 3, wherein the dendritic cell produces IL-10.

### Claim 5 (depends on 4)

The method of claim 4, wherein the dendritic cell is an mDC2.

### Claim 6 (depends on 2)

The method of claim 2, wherein the dendritic cell is a CD1a− dendritic cell.

### Claim 7 (depends on 6)

The method of claim 6, wherein the CD1a− dendritic cell is capable of presenting an antigen to a T cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein the population of mononuclear cells is derived from a human or a non-human animal.

### Claim 9 (depends on 1)

The method of claim 1, further comprising depleting the population of mononuclear cells of T, B and NK cells.

### Claim 10 (depends on 9)

The method of claim 9, comprising depleting the population of mononuclear cells with immunomagnetic beads.

### Claim 11 (depends on 1)

The method of claim 1, comprising deriving the population of mononuclear cells by density gradient separation of standard buffy coat preparations of peripheral blood.

### Claim 12 (depends on 11)

The method of claim 11, further comprising depleting the population of mononuclear cells of T, B and NK cells.

### Claim 13 (depends on 12)

The method of claim 12, comprising depleting the population of mononuclear cells with immunomagnetic beads.

### Claim 14 (depends on 1)

The method of claim 1, wherein the population of peripheral blood or bone marrow mononuclear cells comprises monocytes.

### Claim 15 (depends on 1)

The method of claim 1, wherein the culture medium comprises Iscove's Modified Dulbecco's Medium (IMDM) supplemented with insulin, transferrin, linoleic acid, oleic acid and palmitic acid.

### Claim 16 (depends on 15)

The method of claim 15, wherein the culture medium further comprises approximately 0.25% (w/v) bovine serum albumin and between about 1.5 and 2 mg/L 2-amino ethanol.

### Claim 17 (depends on 15)

The method of claim 15, wherein the dendritic cell is a CD1a− dendritic cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein the dendritic cell substantially lacks L-12 production.

### Claim 19 (depends on 18)

The method of claim 18, wherein the dendritic cell has substantially increased IL-10 production as compared to a dendritic cell produced by culturing a population of peripheral blood or bone marrow mononuclear cells in IL-4, GM-CSF, and a culture medium comprising RPMI.

### Claim 20 (depends on 6, 17)

The method of claim 6 or 17, wherein the CD1a− dendritic cell induces or promotes Th0/Th2 differentiation of T cells.

### Claim 21 (depends on 1)

The method of claim 1, wherein the culture medium comprises Yssel's medium.

### Claim 22 (depends on 21)

The method of claim 21, wherein the Yssel's medium further comprises about 10% fetal bovine serum, about 2 milliMolar (mM) glutamine, about 50 Units/milliliter (U/ml) penicillin and about 100 micrograms/milliliter (jig/ml) streptomycin.

### Claim 23 (depends on 21)

The method of claim 21, wherein the differentiated APC is a dendritic cell.

### Claim 24 (depends on 23)

The method of claim 23, wherein the dendritic cell is a CD1a− dendritic cell.

### Claim 25 (depends on 23)

The method of claim 23, wherein the dendritic cell substantially lacks IL-12 production or induces or promote differentiation of T cells to Th0/Th2.

### Claim 26 (depends on 23)

The method of claim 23, wherein the dendritic cell has substantially increased IL-10 production as compared to a dendritic cell produced by culturing a population of peripheral blood or bone marrow mononuclear cells in IL-4, GM-CSF, and a culture medium comprising RPMI.

### Claim 27 (depends on 23)

The method of claim 23, wherein the CD1a− dendritic cell induces or promotes Th0/Th2 differentiation of T cells.

### Claim 28 (depends on 21)

The method of claim 21, further comprising culturing the APC in the presence of an anti-CD40 monoclonal antibody for a period of approximately 24 hours, thereby providing an activated APC; and culturing the activated APC in the presence of lipopolysaccharide (LPS) and interferon-gamma (IFN-γ) for a period of approximately 48 hours, thereby producing a mature CD83+, CD1a− dendritic cell.

### Claim 29 (depends on 28)

The method of claim 28, wherein the CD83+, CD1a− dendritic cell substantially lacks production of IL-12.

### Claim 30 (depends on 6, 24)

The method of claim 6 or 24, further comprising introducing to at least one CDla dendritic cell at least one exogenous DNA sequence operably linked to a promoter that is capable of controlling expression of said DNA sequence, which at least one exogenous DNA sequence encodes at least one antigen, in an amount sufficient that expression and presentation of the at least one antigen results, thereby producing an antigen presenting CD1a− dendritic cell.

### Claim 31 (depends on 30)

The method of claim 30, further comprising introducing said at least one exogenous DNA sequence to at least one CD1a− dendritic cell by a method selected from electroporation, injection, microinjection, gene gun delivery, lipofection, DOTAP supplemented lipofection, DOSPER supplemented lipofection, or Superfection.

### Claim 32 (depends on 6, 24)

The method of claim 6 or 24, further comprising introducing a sufficient amount of at least one antigen or fragment thereof to at least one CD1a− dendritic cell, such that presentation of the at least one antigen on least one CD1a−0 dendritic cell occurs, thereby producing an antigen presenting CD1a− dendritic cell.

### Claim 33

A differentiated antigen presenting cell (APC), which differentiated APC does not express CDla cell surface marker.

### Claim 34 (depends on 33)

The differentiated APC of claim 33, wherein said differentiated APC comprises a monocyte-derived CD1a− dendritic cell.

### Claim 35 (depends on 34)

The differentiated APC of claim 34, wherein monocyte-derived CD1a− dendritic cell substantially lacks IL-12 production.

### Claim 36 (depends on 34)

The differentiated APC of claim 34, wherein the monocyte-derived CD1a− dendritic cell induces or promotes differentiation of T cells to Th0/Th2 subtypes.

### Claim 37 (depends on 34)

The differentiated APC of claim 34, wherein the monocyte-derived CD1a− dendritic cell is produced by culturing a population of monocytes in interleukin-4 (IL-4), granulocyte macrophage colony stimulating factor (GM-CSF), and a culture medium comprising Iscove's Modified Dulbecco's Medium (IMDM) supplemented with insulin, transferrin, linoleic acid, oleic acid and palmitic acid.

### Claim 38 (depends on 37)

The differentiated APC of claim 37, wherein the culture medium comprises Yssel's medium.

### Claim 39 (depends on 37)

The differentiated APC of claim 37, wherein the monocyte-derived CD1a− dendritic cell has substantially increased IL-10 production as compared to a dendritic cell produced by culturing a population of peripheral blood or bone marrow mononuclear cells in IL4, GM-CSF, and a culture medium comprising RPMI.

### Claim 40 (depends on 34)

The differentiated APC of claim 34, wherein the monocyte-derived CD1a− dendritic cell comprises an mDC2.

### Claim 41 (depends on 34)

The differentiated APC of claim 34, wherein the monocyte-derived CD1a− dendritic cell has a transfection efficiency greater than that of a dendritic cell produced by culturing a population of monocytes in IL-4, GM-CSF, and a culture medium comprising RPMI.

### Claim 42

A method of inducing in a subject an immune response to at least one antigen, said method comprising administering to the subject a population of CD1a− dendritic cells, said CD1a− dendritic cells presenting at least one of said at least one antigen, in an amount sufficient to induce the immune response to said at least one antigen.

### Claim 43 (depends on 42)

The method of claim 42, wherein said CD1a− dendritic cell substantially lacks EL-12 production.

### Claim 44 (depends on 42)

The method of claim 42, wherein said CD1a− dendritic cell is produced by culturing a population of peripheral blood or bone marrow mononuclear cells in interleukin-4 (IL-4), granulocyte macrophage colony stimulating factor (GM-CSF), and a culture medium comprising insulin, transferrin, linoleic acid, oleic acid, palmitic acid for a sufficient time to produce the differentiated antigen presenting cell.

### Claim 45 (depends on 42)

The method of claim 42, wherein the subject is a human or a non-human animal.

### Claim 46

A method of inducing differentiation of T cells, the method comprising: co-culturing a population of T cells with population of CD1a− antigen presenting cells (APC), thereby inducing or promoting differentiation of said T cells.

### Claim 47 (depends on 46)

The method of claim 46, wherein the T cells comprise naive T cells.

### Claim 48 (depends on 46)

The method of claim 46, wherein the antigen presenting cell is a CD1a− dendritic cell.

### Claim 49 (depends on 48)

The method of claim 48, wherein the CD1a− dendritic cell produces substantially no IL-12.

### Claim 50 (depends on 3, 48)

The method of claim 3 or 48, wherein the dendritic cell produces substantially no IL-12 compared to a dendritic cell produced by culturing a population of peripheral blood or bone marrow mononuclear cells in IL-4, GM-CSF, and a culture medium comprising RPMI.

### Claim 51 (depends on 46)

A differentiated T cell produced by the method of claim 46.

### Claim 52

A composition comprising CD1a− dendritic cells.

### Claim 53 (depends on 52)

The composition of claim 52, wherein said CDla dendritic cells are capable of presenting an antigen to a T cell.

### Claim 54 (depends on 52)

The composition of claim 52, wherein said CDla dendritic cells produce substantially no IL-12.

### Claim 55 (depends on 52)

The composition of claim 52, wherein said CD1a− dendritic cells promote differentiation of T cells to a Th0/Th2 subtype.

### Claim 56 (depends on 52)

The composition of claim 52, wherein said CD1a− dendritic cells display or present at least one antigen or antigenic fragment thereof.

### Claim 57 (depends on 56)

The composition of claim 56, wherein the at least one antigen or antigenic fragment comprises a protein or peptide differentially expressed on a cell selected from the group consisting of a tumor cell, a bacterially-infected cell, a parasitically-infected cell, and a virally-infected cell, a target cell of an autoimmune response.

### Claim 58 (depends on 52)

The composition of claim 52, wherein the composition comprises a vaccine.

### Claim 59 (depends on 52)

The composition of claim 52, further comprising a pharmaceutically acceptable carrier.

### Claim 60

A method of inducing or modulating an immune response in an immunocompromised subject, said method comprising administering to the subject a population of CD1a− dendritic cells in an amount sufficient to induce or modulate an immune response in the subject.

### Claim 61

An ex vivo method of inducing in a subject a therapeutic or prophylactic immune response against at least one antigen, the method comprising:
a) culturing a population of monocytes obtained from the subject with IL-4, GM-CSF, and a culture medium comprising Iscove's Modified Dulbecco's Medium (IMDM) supplemented with insulin, transferrin, linoleic acid, oleic acid and palmitic acid for a sufficient time to produce a population of dendritic cells comprising CD1a− dendritic cells;
b) introducing to the population of CD1a− dendritic cells a sufficient amount of at least one antigen, or a sufficient amount of an exogenous DNA sequence operably linked to a promoter that controls expression of said DNA sequence, said DNA sequence encoding at least one or said at least one antigen, such that the presentation of the antigen on the CD1a− dendritic cells results; and
c) administering the antigen-presenting CD1a− dendritic cells to the subject in an amount sufficient to induce a therapeutic or prophylactic immune response against said at least one antigen.

### Claim 62 (depends on 61)

The method of claim 61, wherein the culture medium comprises Yssel's medium.

### Claim 63

A method for therapeutically or prophylactically treating a disease in a subject suffering from said disease, the method comprising:
a) culturing a population of monocytes obtained from the subject with IL-4, GM-CSF, and a culture medium comprising Iscove's Modified Dulbecco's Medium (IMDM) supplemented with insulin, transferrin, linoleic acid, oleic acid and palmitic acid for a sufficient time to produce a population of CD1a− dendritic cells;
b) introducing to the population of CD1a− dendritic cells a sufficient amount of at least one disease-associated antigen, or a sufficient amount of an exogenous DNA sequence operably linked to a promoter that controls expression of said DNA sequence, said DNA sequence encoding at least one of said at least one disease-associated antigen, such that presentation of the disease-associated antigen on the CD1a− dendritic cells results; and
c) administering a therapeutic or prophylactic amount of the CD1a− dendritic cells presenting the disease-associated antigen to the subject to treat said disease.

### Claim 64 (depends on 63)

The method of claim 63, wherein the culture medium comprises Yssel's medium.

### Claim 65

A method for therapeutically or prophylactically treating a disease in a subject suffering from the disease, the method comprising:
a) culturing a population of monocytes obtained from the subject with IL-4, GM-CSF, and a culture medium comprising Iscove's Modified Dulbecco's Medium (IMDM) supplemented with insulin, transferrin, linoleic acid, oleic acid and palmitic acid for a sufficient time to produce a population of CD1a− dendritic cells;
b) contacting the population of CD1a− dendritic cells with a population of diseased cells from a tissue or organ of the subject, thereby inducing presentation of a disease-associated antigen on the CD1a− dendritic cells; and
c) administering a therapeutic or prophylactic amount of CD1a− dendritic cells presenting the disease-associated antigen to the subject to treat the disease.

### Claim 66 (depends on 63)

The method of claim 63, wherein the culture medium comprises Yssel's medium.

### Claim 67 (depends on 63)

The method of claim 63, wherein the disease is a cancer.

### Claim 68

A monocyte-derived dendritic cell, wherein the dendritic cell does not express a CD1a cell marker, substantially lacks EL-12 production, produced IL-1, and promotes Th0/Th2 lineage differentiation of T cells.

### Claim 69

A monocyte-derived dendritic cell produced by culturing a population of monocyte cells in interleukin-4 (IL-4), granulocyte macrophage coloby stimulating factor (GM-CSF), and a culture medium comprising insulin, transferrin, linoleic acid, oleic acid, and palmitic acid, wherein the monocyte-derived dendritic cell has an altered cytokine profile compared to a dendritic cell produced by culturing a population of monocyte cells in IL-4, GM-CSF, and a culture medium comprising RPMI.
